Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo aberto para avaliar segurança e eficácia de CABA-201 em indivíduos com miopatia inflamatória idiopática ativa

12 de novembro de 2026 atualizado por: Cabaletta Bio

Um estudo aberto de fase 1/2 para avaliar a segurança e eficácia de células T receptoras de antígeno quimérico específicas de CD19 autólogas (CABA-201) em indivíduos com miopatia inflamatória idiopática ativa

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Tipo de estudo

Intervencional

Inscrição (Estimado)

74

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Göttingen, Alemanha, 37075
        • Ainda não está recrutando
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Dr. Jana Zschüntzsch
    • California
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • University of California Irvine - Accepting Adult Patients
        • Investigador principal:
          • Tahseen Mozaffar, MD
        • Contato:
      • San Francisco, California, Estados Unidos, 94158
        • Recrutamento
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80046
        • Recrutamento
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Investigador principal:
          • Dr. Kentaro Yomogida, MD
        • Contato:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Recrutamento
        • Mayo Clinic Florida - Accepting Adult Patients
        • Contato:
      • St. Petersburg, Florida, Estados Unidos, 33701
        • Recrutamento
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Investigador principal:
          • Natalie Booth, DO
        • Contato:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30032
        • Recrutamento
        • Emory University - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Estados Unidos, 30029
        • Recrutamento
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Investigador principal:
          • Shanmuganathan Chandrakasan, MD
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Investigador principal:
          • Dr. George Georges, MD
        • Contato:
      • Chicago, Illinois, Estados Unidos, 60637
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Recrutamento
        • University of Kansas Medical Center - Accepting Adult Patients
        • Contato:
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Recrutamento
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Recrutamento
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Investigador principal:
          • Susan Prockop, MD
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48105
        • Recrutamento
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55902
        • Recrutamento
        • Mayo Clinic - Accepting Adult Patients
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10021
        • Recrutamento
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • David R. Fernandez, MD, PhD
      • New York, New York, Estados Unidos, 10021
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Investigador principal:
          • Jae Park, MD
        • Contato:
      • The Bronx, New York, Estados Unidos, 10467
        • Recrutamento
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Recrutamento
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Investigador principal:
          • Saira Sheikh, MD
        • Contato:
      • Durham, North Carolina, Estados Unidos, 27710
        • Recrutamento
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Investigador principal:
          • Kaveh Ardalan, MD, MS
        • Contato:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Recrutamento
        • Oregon Health & Science University - Accepting Adult Patients
        • Contato:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Estados Unidos, 15261
        • Recrutamento
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • Recrutamento
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Contato:
        • Investigador principal:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Recrutamento
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Contato:
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Recrutamento
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Investigador principal:
          • Samuel John, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Houston Methodist Hospital - Accepting Adult Patients
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Investigador principal:
          • Huifang (Linda) Lu, MD
        • Contato:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84113
        • Recrutamento
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Contato:
        • Investigador principal:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Recrutamento
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Contato:
        • Investigador principal:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Ainda não está recrutando
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Investigador principal:
          • Sara Sabbagh, DO
        • Contato:
          • Erin Hammelev - Research Coordinator
          • Número de telefone: 414-337-7064
          • E-mail: ehammele@mcw.edu
      • Roma, Itália, 00165
        • Recrutamento
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Contato:
        • Investigador principal:
          • Professor Franco Locatelli
      • London, Reino Unido, WC1N 3BG
        • Recrutamento
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Reino Unido, SE5 9RS
        • Recrutamento
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Reino Unido, WC1N 3JH
        • Recrutamento
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Contato:
        • Investigador principal:
          • Professor Despina Eleftheriou
      • Manchester, Reino Unido, M13 9WL
        • Recrutamento
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Reino Unido, M6 8HD
        • Recrutamento
        • Salford Royal Hospital - Accepting Adult Patients
        • Contato:
        • Investigador principal:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

6 anos a 75 anos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Outros nomes:
  • Rese-Cel
  • RECABTAGENE AUTOLOLEUCEL
Experimental: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Outros nomes:
  • Rese-Cel
  • RECABTAGENE AUTOLOLEUCEL
Experimental: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Outros nomes:
  • Rese-Cel
  • RECABTAGENE AUTOLOLEUCEL

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Phase 1/2: Incidence and severity of adverse events (AEs)
Prazo: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Prazo: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Prazo: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of adverse events and laboratory abnormalities
Prazo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Prazo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Prazo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Prazo: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Prazo: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Prazo: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Prazo: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Prazo: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Prazo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Prazo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Prazo: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Prazo: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Cadeira de estudo: Medical Director, Cabaletta Bio

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de dezembro de 2023

Conclusão Primária (Estimado)

1 de julho de 2028

Conclusão do estudo (Estimado)

1 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

16 de novembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de novembro de 2023

Primeira postagem (Real)

4 de dezembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .